Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose

Abstract

Fenofibrate-based treatment was associated with improved insulin sensitivity. Atorvastatin did not cause a deterioration in insulin sensitivity. Hypolipidemic therapies resulted in significant changes in the proinflammatory cytokine network as well as in adipokine levels. At the end of the study the measured parameters nearly resembled those of the healthy subjects.

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

“…In addition, pentoxifylline plus fenofibrate treatment showed a significantly better effect on insulin sensitivity than that detected with the fenofibrate treated group. Fenofibrate may improve insulin sensitivity by limiting lipid accumulation in several tissues, including the liver and muscles [14,39,40] and by reducing expression and plasma levels of several adipokines including TNF-a [14,15]. This result HA hyaluronic acid, TGF-b1 transforming growth factor beta 1 a Data obtained after treatment showed significant difference versus data obtained before treatment within group I or group II (p \ 0.05) b Data obtained 24 weeks after treatment in group II showed significant difference versus data obtained 24 weeks after treatment in group I is in accordance with previously reported findings which demonstrated that fenofibrate treatment was associated with significant improvement of insulin sensitivity [16].…”

“…These receptors may also modulate hepatic lipid homeostasis, inflammation and fibrosis, by directing the proliferative and inflammatory response of specific cell types [13]. Furthermore, fenofibrate may improve insulin sensitivity by limiting lipid accumulation in several tissues, including the liver and muscles [14]. This can also be attributed to increased adiponectin together with reduced expression and plasma levels of several other adipokines, including tumor necrosis factor-a (TNF-a), leptin, resistin and plasminogen activator inhibitor (PAI)-1 [14,15].…”

“…Furthermore, fenofibrate may improve insulin sensitivity by limiting lipid accumulation in several tissues, including the liver and muscles [14]. This can also be attributed to increased adiponectin together with reduced expression and plasma levels of several other adipokines, including tumor necrosis factor-a (TNF-a), leptin, resistin and plasminogen activator inhibitor (PAI)-1 [14,15]. Considering its antiinflammatory properties, hypolipidemic and insulin-sensitizing actions it could be assumed that fenofibrate is useful for the prevention and management of NAFLD [16].…”

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

“…This can also be attributed to increased adiponectin together with reduced expression and plasma levels of several other adipokines, including tumor necrosis factor-α (TNF-α), leptin, resistin and plasminogen activator inhibitor (PAI)-1 [66,70,71] . Considering its hypolipidemic and insulin-sensitizing actions it could be assumed that fenofibrate is useful for the prevention and management of NAFLD.…”

“…Interestingly, fenofibrate may improve insulin sensitivity by limiting lipid accumulation in several tissues, including the liver and muscles [66][67][68][69] . This can also be attributed to increased adiponectin together with reduced expression and plasma levels of several other adipokines, including tumor necrosis factor-α (TNF-α), leptin, resistin and plasminogen activator inhibitor (PAI)-1 [66,70,71] .…”